RecruitingNot applicableNCT06040203

Leukocyte-rich PRP or Leukocyte-free PRP vs Placebo in the Treatment of Epicondylitis

Studying Rapidly involuting congenital hemangioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Istituto Ortopedico Rizzoli
Principal Investigator
Enrico Guerra, MD
Istituto Ortopedico Rizzoli - SC Chirurgia della spalla e del gomito
Intervention
Injection of autologous leukocyte rich platelet rich plasma (LR-PRP)(biological)
Enrollment
240 target
Eligibility
18-65 years · All sexes
Timeline
20232027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06040203 on ClinicalTrials.gov

Other trials for Rapidly involuting congenital hemangioma

Additional recruiting or active studies for the same condition.

See all trials for Rapidly involuting congenital hemangioma

← Back to all trials